Pharma4ever A/S Financials, key figures and credit report
Gross profit 16 332.9 kDKK FY 2025 +5.5% vs 2024
EBIT 3 483.1 kDKK FY 2025 +12.1% vs 2024
Net debt -1 815.8 kDKK FY 2025 -56.6% vs 2024
Quick ratio 1.5 FY 2025 -0 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 8 945.62 | 13 009.83 | 15 279.18 | 15 475.54 | 16 332.86 |
| Employee benefit expenses | -6 710.61 | -9 564.85 | -10 203.49 | -12 367.59 | -12 849.81 |
| Total depreciation | -40.88 | -24.84 | -0.48 | ||
| EBIT | 2 194.14 | 3 420.13 | 5 075.22 | 3 107.95 | 3 483.05 |
| Other financial income | 10.17 | 2.80 | 5.61 | 0.89 | |
| Other financial expenses | -13.20 | -12.28 | -5.50 | -11.10 | -0.29 |
| Pre-tax profit | 2 191.11 | 3 407.86 | 5 072.52 | 3 102.46 | 3 483.65 |
| Income taxes | - 484.74 | - 752.78 | -1 128.75 | - 686.25 | - 768.85 |
| Net earnings | 1 706.37 | 2 655.08 | 3 943.77 | 2 416.21 | 2 714.80 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 107.65 | 0.48 | |||
| Tangible assets total | 107.65 | 0.48 | |||
| Investments total | 101.40 | 101.40 | |||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 3 560.71 | 4 974.19 | 7 795.37 | 7 332.42 | 7 811.57 |
| Prepayments and accrued income | 86.42 | 27.00 | |||
| Current other receivables | 11.63 | 609.04 | 34.65 | 34.65 | 5.00 |
| Current deferred tax assets | 85.54 | 133.79 | |||
| Short term receivables total | 3 657.88 | 5 669.66 | 7 857.01 | 7 500.85 | 7 816.57 |
| Cash and bank deposits | 1 109.25 | 580.45 | 1 921.88 | 1 159.39 | 1 815.82 |
| Cash and cash equivalents | 1 109.25 | 580.45 | 1 921.88 | 1 159.39 | 1 815.82 |
| Balance sheet total (assets) | 4 874.79 | 6 250.59 | 9 778.89 | 8 761.64 | 9 733.79 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Shares repurchased | 1 750.00 | 2 650.00 | 4 028.31 | 2 416.21 | 2 714.80 |
| Retained earnings | -1 626.91 | -2 570.54 | -3 943.77 | -2 416.21 | -2 714.80 |
| Profit of the financial year | 1 706.37 | 2 655.08 | 3 943.77 | 2 416.21 | 2 714.80 |
| Shareholders equity total | 2 329.46 | 3 234.54 | 4 528.31 | 2 916.21 | 3 214.80 |
| Provisions | 1.86 | 4.69 | 5.94 | ||
| Non-current liabilities total | |||||
| Current trade creditors | 1 078.36 | 1 123.47 | 3 097.27 | 3 563.90 | 3 621.09 |
| Short-term deferred tax liabilities | 111.96 | 17.50 | 376.85 | ||
| Other non-interest bearing current liabilities | 1 465.11 | 1 775.93 | 2 129.88 | 2 281.52 | 2 521.04 |
| Current liabilities total | 2 543.46 | 3 011.36 | 5 244.64 | 5 845.43 | 6 518.99 |
| Balance sheet total (liabilities) | 4 874.79 | 6 250.59 | 9 778.89 | 8 761.64 | 9 733.79 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated